Faculty

Ashok Seshadri, M.D.

Clinical Studies

An 8 week Randomized Double Blind Placebo Controlled Multi-site Study assessing Efficacy and Safety of MYDAYIS® (d-amphetamine / l-amphetamine) for Bipolar Depression Rochester, Minn., Eau Claire, Wis., Austin, Minn.
The purpose of this study is to assess the effectiveness and safety of MYDAYIS® as an augmentation agent for bipolar depression.

Mood Stabilizer Pharmacogenomics Biobank (MoStGEN) Austin, Minn., Scottsdale/Phoenix, Ariz., Mankato, Minn., Rochester, Minn.
The purpose of this study is to create a larger database and bio-repository to examine pharmacogenomics in patients with BD type I and type II treated with mood stabilizing anticonvulsants, atypical antipsychotics and antidepressant medications.
Randomized Controlled Trial of Stress Management and Resiliency Training for Depression (SMART-D) vs Treatment as Usual in the Treatment of Major Depression Rochester, Minn., Austin, Minn., Red Wing, Minn., Albert Lea, Minn.
The primary purpose of this study is to compare outcomes of depressive symptoms (PHQ-9 and HAM-D) over 6 months following an eight-week program of SMART-D therapy + treatment as usual versus treatment as usual for patients with major depression in partial-to full-remission.
Stress Management and Resiliency Training (SMART) Integrated Into Comprehensive Treatment of Major Depression: A Feasibility Study Austin, Minn., Rochester, Minn.
The investigators are doing this research study to find out if the Stress Management and Resiliency Training (SMART) therapy will help subjects with their major depression treatment.